Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the US Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a ...
And although it's a signal that branded versions of tirzepatide-based drugs – Mounjaro, for diabetes, and Zepbound, approved at the end of 2023 for weightloss – are more widely available ...
Results that may be inaccessible to you are currently showing.